Abstract
This chapter will attempt to accomplish a seemingly impossible task of characterizing the concept of quality of life in terms of pleasure centres, neuronal circuits and chemical mechanisms in the brain. The supporting explanations will be presented in three parts: first, identifying three key characteristics of quality of life – first, the central doctrine of subjectivity, the time frame of appraisal, and the relevance of immediate affective tone in determining quality of life ratings; second, a review of the cumulative knowledge on the neuroanatomical and neurochemical mechanisms underlying subjective responses to pleasurable stimuli such as food and drugs. Thirdly, evidence is presented to support that interference with these brain reward mechanisms leads to feelings of lack of pleasure and poor quality of life, citing antipsychotic drug therapy in schizophrenia as an example. Laboratory experiments in animals and neurochemical imaging studies in humans suggest that dopaminergic mechanisms in nucleus accumbens, amygdala, hippocampus and prefrontal cortex are key players in determining the qualitative and quantitative aspects of subjective responses to pleasurable stimuli. Antipsychotic drug induced dopaminergic blockade in these neuronal circuits leads to persistent feelings of dysphoria and pervasive lack of pleasure, leading to subjective distress and compromised quality of life. The nuances of subjective responses to antipsychotic drugs thus have enormous implications for long term care of the mentally ill people
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hornquist JO. The concept of quality of life. Scandinavian Journal of Social Medicine. 1982;10:57–61.
Cohen C. On the quality of life: some philosophical reflections. Circulation 1982;66(suppl.111): s29–s33.
Campbell A, Converse P, Rogers W. The quality of American life. New York: Russel Sage Foundation, 1976.
Diener E. Subjective Well-Being. Psychological Bulletin 1984;95(3):542–575.
George L, Bearon I. Quality of life in older persons: meaning and measurement. New York: Human Sciences Press, 1980.
Voruganti L, Heslegrave H, Awad AG & Seeman MV. Quality of life measurement in Schizophrenia – Reconciling the quest for subjectivity with the question of reliability. Psychological Medicine 1998;28:165–172.
Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997; 6(1):21–6.
Corten P, Mercier C, Pelc I. ‘‘Subjective quality of life’’: clinical model for assessment of rehabilitation treatment in psychiatry. Social Psychiatry and Psychiatric Epidemiology 1994; 29:178-183.
Goethe JW & Fisher EH. Functional impairment in depressed patients. Journal of Affective Disorders, 1995;33: 23–29.
Wells KB, Stewart A, Hays RD et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989;262:914–919.
Voruganti LP, Awad AG. Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatr Scand Suppl. 2005;(427):22–8.
Allison PJ, Locker D, Feine JS. Quality of life: a dynamic construct. Social science and medicine 1997;45:221–230.
Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004; 12(6):305–20.
Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996;6:243–51.
James GA, Gold MS, Liu Y. Interaction of satiety and reward response to food stimulation. J Addict Dis. 2004;23(3):23–37.
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403–13.
Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O’Dell LE, Parsons LH, Sanna PP. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;27(8):739–49.
Risinger RC, Salmeron BJ, Ross TJ, Amen SL, Sanfilipo M, Hoffmann RG, Bloom AS, Garavan H, Stein EA. Neural correlates of high and craving during cocaine self-administration using BOLD fMRI. Neuroimage. 2005;26(4):1097–108.
Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology. 2004;47 Suppl 1:3–13.
Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47 Suppl 1:227–41.
Salamone JD, Correa M, Mingote SM, Weber SM. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol. 2005;5(1):34–41.
Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl). 2004;171(2):121–32.
Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia – Findings from an in vivo SPECT study. Schizophr Res. 2006 Sep 1; [Epub ahead of print].
Tsibulsky VL, Norman AB. Real time computation of in vivo drug levels during drug self-administration experiments. Brain Res Brain Res Protoc. 2005;15(1):38–45.
Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36(7):1182–90.
de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303–9.
Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57(2–3):201–8.
Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging.Neuropsychopharmacology. 2001;25:642–50.
Koivumaa-Honkanen H-T, Viinamaki H, Honkanen R, Tanskanen A, Antikainen R, Niskanen L, Jaaskelainen J, Lehtonen J, Correlates of Life satisfaction among psychiatric patients. Acta Psychiatrica Scandinavica. 1996;94:372–378.
Awad AG & Voruganti LP. Neuroleptic dysphoria, comorbid drug abuse in schizophrenia and the emerging science of subjective tolerability: towards a new synthesis. J Dual Diagnosis 2005;1(2):83–94.
Lehman A. The well-being of chronic mental patients: assessing their quality of life. Archives of General Psychiatry 1983;40:369–373.
Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction. 2000;95 Suppl 2:S119–28.
Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis. 1997;185(7):463–5.
Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001;107(3):173–7.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 springer
About this chapter
Cite this chapter
Voruganti, L.N., Awad, A.G. (2007). Role of Dopamine in Pleasure, Reward and Subjective Responses to Drugs. In: Ritsner, M.S., Awad, A.G. (eds) Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5779-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4020-5779-3_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-5777-9
Online ISBN: 978-1-4020-5779-3
eBook Packages: MedicineMedicine (R0)